Active Filter(s):
Details:
Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.
Lead Product(s): Rislenemdaz
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Cerecor
Deal Size: $22.1? million Upfront Cash: Undisclosed
Deal Type: Acquisition February 03, 2020